d614
Vaccineexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Feb 24, 2021 (NCT04762680)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05289037 | Phase 1/Phase 2 (Phase 2) | Mar 30, 2022 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05124171 | Phase 3 | Nov 30, 2021 | Assistance Publique - Hôpitaux de Paris, COVIREIVAC |
| NCT04762680 | Phase 2/Phase 3 (Phase 3) | Feb 24, 2021 | GlaxoSmithKline, Sanofi, Sanofi-Aventis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2021 |
| COVIREIVAC | Academic/Hospital | 1 | 0 | 1 | 2021 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2021 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2022 |
| Sanofi | For profit | 1 | 0 | 1 | 2021 |
| Sanofi-Aventis | For profit | 1 | 1 | 1 | 2021 |
6 organizations
Page 1 / 1